Featured Stories
Royal Marsden NHS Foundation Trust: World-First Approach to Precision Diagnostics in Multiple Myeloma Care
LONDON, England, Oct. 31 -- The Royal Marsden National Health Service Foundation Trust issued the following news:
* * *
A world-first approach to precision diagnostics in multiple myeloma care
The Royal Marsden is advancing precision diagnostics and shaping the future of myeloma care with the launch of MyTrack(TM) Myeloma
30 October 2026
Written by Dr Kevin Boyd, Consultant Haematologist, The Royal Marsden
Multiple myeloma is a complex and highly variable cancer, as the disease can behave differently from one individual to another. This variability presents a fundamental challenge: how do
... Show Full Article
LONDON, England, Oct. 31 -- The Royal Marsden National Health Service Foundation Trust issued the following news:
* * *
A world-first approach to precision diagnostics in multiple myeloma care
The Royal Marsden is advancing precision diagnostics and shaping the future of myeloma care with the launch of MyTrack(TM) Myeloma
30 October 2026
Written by Dr Kevin Boyd, Consultant Haematologist, The Royal Marsden
Multiple myeloma is a complex and highly variable cancer, as the disease can behave differently from one individual to another. This variability presents a fundamental challenge: how dowe ensure that each patient receives care that is truly tailored to their disease biology and personal circumstances?
This is where precision diagnostics has the potential to transform the diagnostic and treatment pathway. The Royal Marsden's MyTrack(TM) Myeloma is a ground-breaking, advanced diagnostic solution designed to enable personalised treatment and improve patient outcomes.
From innovation to clinical impact
The development of MyTrack(TM) Myeloma represents a significant step forward in the management of this condition. It combines standard diagnostic testing with three innovative, personalised genomic and disease-monitoring tests within a single integrated pathway. This world-first diagnostic framework supports decision-making across the entire patient journey, from diagnosis through to long-term disease monitoring.
At diagnosis, enhanced tumour profiling allows us to more accurately identify patients with aggressive disease. This enables clinicians to adapt treatment strategies earlier and, if needed, escalate the approach from the outset.
Later in the pathway, highly sensitive minimal residual disease tracking provides a deeper understanding of how well a patient is responding to treatment. This long-term monitoring of remission depth can inform whether planned treatment breaks are a safe and evidence-based possibility for suitable patients.
Enabling a new era of personalised myeloma care
For people living with myeloma, the 'one-size-fits-all' continuous therapy approach can carry both physical and psychological impacts. Patients may experience ongoing side effects, and the need for long-term therapy can reduce quality of life.
The possibility of a treatment-free interval, when clinically appropriate, is highly meaningful. However, implementing this safely requires a level of precision that has previously been challenging.
MyTrack(TM) Myeloma addresses this gap. By combining detailed risk profiling with highly sensitive monitoring, it can provide clinicians and patients with the confidence to make more personalised and informed decisions. As a result, care can be tailored to the biology of the disease, the response depth of the patient, as well as their individual priorities.
Driving global leadership in myeloma care
The pathway is designed through years of clinical research leadership at The Royal Marsden, translating insights from world-renowned haematology experts and leading clinical studies into a new approach of how precision diagnostics can be applied in practice.
The Royal Marsden is committed to leading change and advancing international guidelines and clinical standards that will define how myeloma is managed for years to come.
I believe that patient outcomes can be improved by using this pathway and the ambition is for MyTrack(TM) Myeloma to become the gold standard for anyone diagnosed with multiple myeloma.
Supporting clinicians, empowering patients
MyTrack(TM) Myeloma is currently available for private patients and has been designed to integrate seamlessly with local care. By sending the patient's bone marrow and blood sample, referring clinicians will receive a comprehensive, integrated, expert-led report that combines all the diagnostic insights into a clear, concise format. This supports individualised care and enables more effective, evidence-based shared decision-making.
Ultimately, our goal is to improve the outcomes and quality of life for people living with myeloma, and with this pathway, patients can receive advanced, individualised care.
MyTrack(TM) Myeloma is initially available to private patients, but The Royal Marsden's ambition is to work with the NHS to bring this pioneering pathway to more patients in the future.
Explore our MyTrack(TM) Myeloma service page (https://www.royalmarsden.nhs.uk/services/mytrack-myeloma) to learn more about the pathway, watch our video FAQs and find out how to contact the team.
* * *
Original text here: https://www.royalmarsden.nhs.uk/news-and-events/news/world-first-approach-precision-diagnostics-multiple-myeloma-care
RSE Publishes Year in Review 2025-2026
EDINBURGH, Scotland, Oct. 31 (TNSrpt) -- The Royal Society of Edinburgh issued the following news:
* * *
29 October 2026
RSE publishes Year in Review 2025-2026
Highlights of the session April 2025-March 2026 have been published in the RSE's year in review.
-
The Royal Society of Edinburgh was established over 240 years ago for the 'advancement of learning and useful knowledge'. Those founding principles continue to guide the RSE's work today.
The RSE is a multidisciplinary and independent organisation, using the knowledge and expertise of 1,800 Fellows to provide expert analysis and advice
... Show Full Article
EDINBURGH, Scotland, Oct. 31 (TNSrpt) -- The Royal Society of Edinburgh issued the following news:
* * *
29 October 2026
RSE publishes Year in Review 2025-2026
Highlights of the session April 2025-March 2026 have been published in the RSE's year in review.
-
The Royal Society of Edinburgh was established over 240 years ago for the 'advancement of learning and useful knowledge'. Those founding principles continue to guide the RSE's work today.
The RSE is a multidisciplinary and independent organisation, using the knowledge and expertise of 1,800 Fellows to provide expert analysis and adviceon major societal challenges. In doing so, the RSE supports the cultural, economic, environmental, and social wellbeing of Scotland and its people.
Amongst a range of activities, the year in review showcases the RSE's policy work in the run up to May's Scottish Parliament elections. As Scotland's National Academy, the RSE was well-positioned to provide independent advice and evidence-informed analysis for the benefit of policymakers and the public alike.
The report also features the RSE's public engagement and schools programmes, the prestigious research awards offering, and the RSE's international work.
* * *
REPORT: https://rse.org.uk/wp-content/uploads/2026/10/RSE-Year-in-Review-2025-26.pdf
* * *
Original text here: https://rse.org.uk/rse-publishes-year-in-review-2025-2026/
RSE President Responds to UK Autumn Budget 2026
EDINBURGH, Scotland, Oct. 31 -- The Royal Society of Edinburgh issued the following news:
* * *
30 October 2026
RSE President responds to UK Autumn Budget 2026
Responding to the UK Government's Autumn Budget, Professor Sir Anton Muscatelli FRSE, President of the Royal Society of Edinburgh, said:
"We welcome the UK Government's recognition of the importance of research and innovation to economic growth and national prosperity, including new investment in technologies and capabilities in which Scotland has considerable strengths.
"However, investment in innovation must go hand in hand with
... Show Full Article
EDINBURGH, Scotland, Oct. 31 -- The Royal Society of Edinburgh issued the following news:
* * *
30 October 2026
RSE President responds to UK Autumn Budget 2026
Responding to the UK Government's Autumn Budget, Professor Sir Anton Muscatelli FRSE, President of the Royal Society of Edinburgh, said:
"We welcome the UK Government's recognition of the importance of research and innovation to economic growth and national prosperity, including new investment in technologies and capabilities in which Scotland has considerable strengths.
"However, investment in innovation must go hand in hand withsustained support for fundamental, curiosity-driven research. The discoveries that underpin tomorrow's economic and societal advances often emerge from research whose applications cannot be predicted in advance. A strong and financially sustainable university sector is essential to this endeavour.
"For Scotland, the picture is particularly complex. Our research and innovation ecosystem operates across both UK-wide and devolved funding arrangements, and the implications of this Budget will need to be considered alongside the forthcoming Scottish Budget and the decisions that follow.
"As Scotland's National Academy, the RSE will continue to champion the value of research across all disciplines, and the importance of ensuring that investment in knowledge and innovation delivers lasting benefits for communities, businesses and society throughout Scotland."
* * *
Original text here: https://rse.org.uk/rse-president-responds-to-uk-autumn-budget-2026/
Treatment = Life: AHF Reaches 2 Million Patients in Care in Africa
LOS ANGELES, California, Oct. 30 -- The AIDS Healthcare Foundation posted the following news:
* * *
Treatment = Life: AHF Reaches 2 Million Patients in Care in Africa
*
AIDS Healthcare Foundation (AHF) has surpassed 2 million patients in care across 15 African countries, marking a historic achievement 25 years after beginning its first programs outside the United States in South Africa and Uganda. With programs in four additional countries expected to launch in 2027, AHF is recognizing the communities and partnerships behind this progress while calling for urgent action to close persistent
... Show Full Article
LOS ANGELES, California, Oct. 30 -- The AIDS Healthcare Foundation posted the following news:
* * *
Treatment = Life: AHF Reaches 2 Million Patients in Care in Africa
*
AIDS Healthcare Foundation (AHF) has surpassed 2 million patients in care across 15 African countries, marking a historic achievement 25 years after beginning its first programs outside the United States in South Africa and Uganda. With programs in four additional countries expected to launch in 2027, AHF is recognizing the communities and partnerships behind this progress while calling for urgent action to close persistentgaps in the HIV response.
AHF's work in Africa began in 2001 with modest programs when antiretroviral therapy was beyond the reach of most people on the continent. At the time, only about 5% of the 21 million patients in need were receiving treatment. Combining direct care with advocacy for affordable medicines, AHF worked alongside governments and communities to help make lifesaving treatment accessible.
The milestone brings AHF's "Treatment = Life" message into focus: HIV treatment is prevention. People who achieve viral suppression do not transmit HIV. Treatment keeps people alive, healthy, and able to pursue their futures. These benefits require early diagnosis, prompt treatment, and uninterrupted care.
"Two million patients in care means millions more family and community members whose lives are better because their loved ones are alive and thriving," said Dr. Penninah Iutung, AHF Executive Vice President - Global. "By keeping people healthy, antiretroviral treatment helps them live fulfilling lives--strengthening productivity, household incomes, and communities' social and economic wellbeing. That is what 'Treatment = Life' means, and it is what makes this milestone so meaningful."
Yet testing is still lagging, prevention remains off track, and too many people go without treatment or fall out of care. These practical gaps threaten progress and demand renewed political commitment.
"This progress took activism, research, political will, and people working together--from communities to governments--because they refused to accept that millions should die without treatment," said Martin Matabishi, AHF Africa Bureau Chief. "We must reaffirm our commitment to the HIV response. We must reach people who do not know their HIV status, expand prevention, and ensure everyone who starts treatment stays on it. HIV is not over."
AHF calls on governments and partners to protect the gains made in the HIV response by sustaining HIV funding, expanding testing and prevention services, ensuring uninterrupted antiretroviral therapy (ART) access and retaining patients in care. "Treatment = Life" embodies AHF's commitment to supporting Africa's efforts to advance the AIDS response and achieve the goal of HIV control.
***
Original text here: https://www.aidshealth.org/2026/10/treatment-life-ahf-reaches-2-million-patients-in-care-in-africa/
Royal Society of Edinburgh: African Scientific Links With Scotland Formalised Through New Partnership
EDINBURGH, Scotland, Oct. 30 -- The Royal Society of Edinburgh issued the following news:
* * *
29 October 2026
African scientific links with Scotland formalised through new partnership
The RSE and the African Academy of Sciences signed a Memorandum of Understanding at the Royal Society of Edinburgh building on the Monday 19 October.
The agreement is the second between the RSE and an academy in Africa - the first being the MoU with The Academy of Sciences, Malawi (TAS) - which was signed in Lilongwe in February of this year.
The African Academy of Sciences (AAS) was founded in 1985, with
... Show Full Article
EDINBURGH, Scotland, Oct. 30 -- The Royal Society of Edinburgh issued the following news:
* * *
29 October 2026
African scientific links with Scotland formalised through new partnership
The RSE and the African Academy of Sciences signed a Memorandum of Understanding at the Royal Society of Edinburgh building on the Monday 19 October.
The agreement is the second between the RSE and an academy in Africa - the first being the MoU with The Academy of Sciences, Malawi (TAS) - which was signed in Lilongwe in February of this year.
The African Academy of Sciences (AAS) was founded in 1985, withthe mandate to improve lives through science. The African Academy recognises excellence through its fellowship and award schemes across the continent, providing non-political advice through its think-tank functions to shape Africa's science, technology and innovation sector, and implementing key programmes aimed at addressing Africa's developmental challenges.
The African delegation was welcomed by RSE chief executive Professor Sarah Skerratt. AAS President Professor Friday Okonofua FAS signed the MoU for the African Academy, with RSE Vice President, International, Professor James Njuguna FRSE signing on behalf of the RSE.
Professor Okonofua said: "The fact that we are here today to sign reflects the commitment required to bring an international institutional partnership to function and to action. So I thank everyone on both sides, on our side and your side, whose patience and engagement and hard work have brought us to this very important moment."
He added: "We believe that science flourishes when researchers work across multidiscipline geographical lines, when they exchange ideas freely, and they have a common approach to challenges."
Professor Njuguna added: "We hope to create a new beginning chapter for Scotland and Africa in terms of this collaboration, and not just for the science, but also for widening opportunities across the two continents. Because the true value of collaboration is not just simply sharing what we know, but also discussing what we would like it to become."
The MoU will support early career researchers, collaborative research, policy advice and resource mobilisation, with a specific focus on areas where Scotland and African countries share challenges, such as health, climate change pressures, food security, technology and sustainable growth.
* * *
Original text here: https://rse.org.uk/african-scientific-links-with-scotland-formalised-through-new-partnership/
Meet Ari: Foundation Launches Partnership with Citizen Health
DANVERS, Massachusetts, Oct. 30 -- The National Scleroderma Foundation posted the following news:
* * *
Meet Ari: Foundation Launches Partnership with Citizen Health
*
Most people with autoimmune conditions already keep their own records: a spreadsheet of results, a running list of medicines and who prescribed them, or notes typed into a phone in the parking lot before an appointment.
It is a lot of documentation. It is a lot of work.
The National Scleroderma Foundation is proud to launch a partnership with Citizen Health to make that work a lot easier. Meet Ari, the AI teammate for your
... Show Full Article
DANVERS, Massachusetts, Oct. 30 -- The National Scleroderma Foundation posted the following news:
* * *
Meet Ari: Foundation Launches Partnership with Citizen Health
*
Most people with autoimmune conditions already keep their own records: a spreadsheet of results, a running list of medicines and who prescribed them, or notes typed into a phone in the parking lot before an appointment.
It is a lot of documentation. It is a lot of work.
The National Scleroderma Foundation is proud to launch a partnership with Citizen Health to make that work a lot easier. Meet Ari, the AI teammate for yourscleroderma journey.
Ari takes the lead and helps you manage everything you need to know about your care.
Keeps records from all your specialists together in one place you control, so results from each appointment are ready for the next
Keeps your history, medicines, and care team information ready to share with each new doctor--even those unfamiliar with your condition--so you only need to tell your story once
Tracks your key symptoms between appointments in your own words, so you can share an accurate picture of how you've been feeling
Reads an insurance denial, drafts the appeal, and files it with your approval
Gets benefits and work paperwork started early, since approvals often take longer than expected
Helps you prepare questions for each appointment and stay on top of follow-ups
Work with Ari through text messages, so there is no app to download and no new portal to remember. You can use voice memos on a hard day, type your notes on a good one, or send a photo of a results letter or an insurance form. Ari flags what needs your attention without prompting and always asks for your approval before taking action.
Visit the dedicated landing page for the National Scleroderma community: https://scleroderma.org/Ari. Ready to learn more? Register for our upcoming webinar with the team from Citizen Health who will go in-depth on what you can expect when you team up with Ari.
***
Original text here: https://scleroderma.org/meet-ari-foundation-launches-partnership-with-citizen-health/ (TNSmlt)
AHF Hails Introduction of Protect 340B Act of 2026
LOS ANGELES, California, Oct. 30 -- The AIDS Healthcare Foundation posted the following news:
* * *
AHF Hails Introduction of Protect 340B Act of 2026
*
WASHINGTON (October 30, 2026) AIDS Healthcare Foundation (AHF) welcomes the PROTECT 340B Act of 2026 introduced yesterday by Representatives Doris Matsui (D-CA) and Tracey Mann (R-KS) and a cadre of bipartisan cosponsors. The legislation would terminate the Trump administration's rebate model pilot program before its planned implementation on January 1, 2027 - if implemented, the pilot initiative would change how nonprofit healthcare providers
... Show Full Article
LOS ANGELES, California, Oct. 30 -- The AIDS Healthcare Foundation posted the following news:
* * *
AHF Hails Introduction of Protect 340B Act of 2026
*
WASHINGTON (October 30, 2026) AIDS Healthcare Foundation (AHF) welcomes the PROTECT 340B Act of 2026 introduced yesterday by Representatives Doris Matsui (D-CA) and Tracey Mann (R-KS) and a cadre of bipartisan cosponsors. The legislation would terminate the Trump administration's rebate model pilot program before its planned implementation on January 1, 2027 - if implemented, the pilot initiative would change how nonprofit healthcare providersaccess their prescription drug purchase savings - from upfront discounts to rebates on the back end of transactions. In addition, the bill would prohibit pharmacy benefit managers (PBMs) from subjecting 340B safety-net providers to discriminatory reimbursements, unfair fees, and restrictive pharmacy networks.
The legislation would preserve the status quo for how nonprofit providers access the savings they rely upon for delivering high-quality health services to low-income Americans. The pharmaceutical industry prefers converting 340B to a rebate program in which every prescription drug purchase becomes subject to dispute and protracted payment.
"The 340B program is a critical lifeline for providers like AHF that care for people living with HIV as well as rural providers already operating on shoestring budgets that need their savings upfront just to keep their doors open. Ultimately, the bill stops drug companies that want to delay and deny how safety-net providers get their savings and bars abusive practices by PBMs that siphon away savings Congress intended to strengthen the healthcare safety-net," said John Hassell, National Director of Advocacy for AHF.
With the rebate pilot program set to take effect on January 1, 2027, there is no time to waste. AHF encourages lawmakers who understand the critical importance of 340B to enact their legislative agenda before the end of the 119th Congress.
***
Original text here: https://www.aidshealth.org/2026/10/ahf-hails-introduction-of-protect-340b-act-of-2026/
